A randomized, double-blind comparison of risedronate and etidronate in the treatment of paget’s disease of bone
| Autor: | Pirow J. Bekker, Jacques P. Brown, Douglas Wayne Axelrod, Ethel S. Siris, Mohammad S. Hoseyni, Paul D. Miller |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
medicine.medical_specialty
Deoxypyridinoline Randomization Bone disease business.industry General Medicine Etidronic acid medicine.disease Gastroenterology Surgery chemistry.chemical_compound Paget's disease of bone Tolerability chemistry Internal medicine Risedronic acid medicine Alkaline phosphatase business medicine.drug |
| Zdroj: | The American Journal of Medicine. 106:513-520 |
| ISSN: | 0002-9343 |
| DOI: | 10.1016/s0002-9343(99)00062-5 |
| Popis: | PURPOSE: To compare the efficacy and tolerability of oral risedronate and etidronate for treatment of Paget's disease of bone. PATIENTS AND METHODS: Patients from 12 centers in North America received risedronate 30 mg daily for 2 months (62 patients) or etidronate 400 mg daily for 6 months (61 patients) in a prospective, randomized, double-blind study. Serum alkaline phosphatase (the primary variable), serum bone-specific alkaline phosphatase, and urinary deoxypyridinoline concentrations were monitored for 12 to 18 months. RESULTS: Serum alkaline phosphatase concentration normalized by month 12 in 73% of risedronate-treated patients, compared with 15% of those receiving etidronate ( P 360 days for etidronate-treated patients ( P P P P CONCLUSION: Although etidronate is effective, risedronate offers a shorter duration of therapy, better and longer-lasting remission, significant reductions in pain, and provides additional remission in subjects who exhibited an incomplete response to previous etidronate treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|